141 related articles for article (PubMed ID: 29998365)
1. Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial.
Dittrich C; Königsberg R; Mittlböck M; Geissler K; Sahmanovic-Hrgovcic A; Pleiner-Duxneuner J; Czejka M; Buchner P
Invest New Drugs; 2019 Feb; 37(1):127-138. PubMed ID: 29998365
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.
Chadha AS; Skinner HD; Gunther JR; Munsell MF; Das P; Minsky BD; Delclos ME; Chatterjee D; Wang H; Clemons M; George G; Singh PK; Katz MH; Fleming JB; Javle MM; Wolff RA; Varadhachary GR; Crane CH; Krishnan S
PLoS One; 2016; 11(6):e0156910. PubMed ID: 27336466
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
[TBL] [Abstract][Full Text] [Related]
4. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
Das P; Eng C; Rodriguez-Bigas MA; Chang GJ; Skibber JM; You YN; Maru DM; Munsell MF; Clemons MV; Kopetz SE; Garrett CR; Shureiqi I; Delclos ME; Krishnan S; Crane CH
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):301-5. PubMed ID: 24315563
[TBL] [Abstract][Full Text] [Related]
5. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
[TBL] [Abstract][Full Text] [Related]
6. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
Kumar R; Lu SK; Minchom A; Sharp A; Davidson M; Gunapala R; Yap TA; Bhosle J; Popat S; O'Brien ME
Cancer Chemother Pharmacol; 2016 Feb; 77(2):375-83. PubMed ID: 26706729
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
[TBL] [Abstract][Full Text] [Related]
9. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Ma WW; Xie H; Fetterly G; Pitzonka L; Whitworth A; LeVea C; Wilton J; Mantione K; Schihl S; Dy GK; Boland P; Iyer R; Tan W; Brady W; Straubinger RM; Adjei AA
Am J Clin Oncol; 2019 Feb; 42(2):184-189. PubMed ID: 30418178
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.
Gruber A; Czejka M; Buchner P; Kitzmueller M; Kirchbaumer Baroian N; Dittrich C; Sahmanovic Hrgovcic A
Cancer Chemother Pharmacol; 2018 Apr; 81(4):763-771. PubMed ID: 29453635
[TBL] [Abstract][Full Text] [Related]
11. A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Murray Stewart T; Von Hoff D; Fitzgerald M; Marton LJ; Becerra CHR; Boyd TE; Conkling PR; Garbo LE; Jotte RM; Richards DA; Smith DA; Stephenson JJ; Vogelzang NJ; Wu HH; Casero RA
Cancer Chemother Pharmacol; 2021 Jan; 87(1):135-144. PubMed ID: 33215270
[TBL] [Abstract][Full Text] [Related]
12. Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Ahn PH; Machtay M; Anne PR; Cognetti D; Keane WM; Wuthrick E; Dicker AP; Axelrod RS
Am J Clin Oncol; 2018 May; 41(5):441-446. PubMed ID: 27391356
[TBL] [Abstract][Full Text] [Related]
13. A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.
Brenner B; Sarfaty M; Purim O; Kundel Y; Amit L; Abramovich A; Sadeh Gonik U; Idelevich E; Gordon N; Medalia G; Sulkes A
PLoS One; 2016; 11(7):e0157548. PubMed ID: 27390847
[TBL] [Abstract][Full Text] [Related]
14. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.
Tamiya M; Tamiya A; Shiroyama T; Takeoka S; Naito Y; Omachi N; Kimura Y; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Invest New Drugs; 2018 Aug; 36(4):608-614. PubMed ID: 29101518
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
[TBL] [Abstract][Full Text] [Related]
16. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
Gulhati P; Raghav K; Shroff RT; Varadhachary GR; Kopetz S; Javle M; Qiao W; Wang H; Morris J; Wolff RA; Overman MJ
Cancer; 2017 May; 123(6):1011-1017. PubMed ID: 27859010
[TBL] [Abstract][Full Text] [Related]
19. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
